CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 03:46 am IST
Share
CNS Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 3.42 million compared to USD 3.81 million a year ago. Basic loss per share from continuing operations was USD 2.7 compared to USD 4.2 a year ago. Diluted loss per share from continuing operations was USD 2.7 compared to USD 4.2 a year ago.
For the nine months, net loss was USD 9.77 million compared to USD 11.24 million a year ago. Basic loss per share from continuing operations was USD 7.5 compared to USD 12.9 a year ago. Diluted loss per share from continuing operations was USD 7.5 compared to USD 12.9 a year ago.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.